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Edited by Masayuki MiyasakaAbstract B cell activating factor belonging to the TNF family
(BAFF) is a novel member of the tumor necrosis factor (TNF) li-
gand family and plays an important role in B lymphocyte matu-
ration and survival. Overexpression of BAFF is closely involved
in the pathogenesis and progression of many kinds of autoimmune
disorders; therefore, BAFF has been considered as an ideal ther-
apeutic target for these conditions. In this study, we generated
several candidate immune inhibitors of human BAFF by conju-
gating foreign immunodominant T-helper cell (Th) epitopes to
the N- or C-terminus of ﬁve BAFF mutants. The recombined pro-
teins were successfully expressed in Escherichia coli (E. coli) and
puriﬁed by Ni-NTA chromatography. BALB/c mice immunized
with the recombinant proteins produced high levels of anti-BAFF
antibodies, and their sera inhibited the lymphocyte proliferation-
inducing activity of recombinant soluble BAFF and natural solu-
ble BAFF. Moreover, antibodies cross-reactive with BAFF were
detected in sera from hu-SCID mice immunized with the recom-
binant proteins. These results indicated that the recombinant
BAFF mutants modiﬁed with Th epitopes could induce neutraliz-
ing antibodies against BAFF in vivo. This study may provide a valu-
able strategy for treating BAFF-associated autoimmune diseases.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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B cell activating factor belonging to the TNF family
(BAFF), a member of the tumor necrosis factor (TNF) ligand
superfamily, is also known as B lymphocyte stimulator
(BLyS), TNF homologue that activates apoptosis, nuclear fac-
tor jB, and c-jun NH2-terminal kinase (THANK), TNF and
apoptosis ligand-related leukocyte-expressed ligand1 (TALL-
1) and zTNF4 [1–5]. As a type II transmembrane protein,
BAFF is either expressed as a membrane bound molecule or
cleaved into a soluble cytokine. The membrane bound mole-
cule comprises 285 amino acids. The soluble BAFF (sBAFF)
consists of 152 amino acids (residual 134–285), which is the
extracellular fragment of the membrane bound molecule
released by proteolysis and is the principal active domain of
BAFF [6]. Both forms of BAFF have similar functions. UnderAbbreviations: BAFF, B cell activating factor belonging to the TNF
family; sBAFF, soluble BAFF; Th, T-helper cell; msBAFF, sBAFF
mutant; HEL, hen egg-white lysozyme
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doi:10.1016/j.febslet.2006.12.060physiologic conditions, BAFF in trimeric form regulates the
proliferation and function of T and B lymphocytes by binding
to three diﬀerent receptors, namely, BAFF-R, TACI, and
BCMA [7]. Overexpression of BAFF in mice results in autoim-
mune lupus-like traits including high levels of rheumatoid fac-
tors, proteinuria, anti-DNA autoantibodies, and increased B
cells and eﬀector T cells [8–12]. Treatment of bona ﬁde SLE
mice with BAFF antagonists slows down disease progression
and increases survival [13–16]. BAFF overexpression is
common in human SLE, RA and SS [12,17,18]. Furthermore,
serum sBAFF levels correlate with the severity of BAFF-asso-
ciated diseases [19,20]. These ﬁndings suggest that BAFF may
be a promising therapeutic target for human BAFF-associated
autoimmune diseases.
In 1999, Dalum et al. [21] reported that foreign T-helper cell
(Th) epitope-modiﬁed mutant cytokines may act as new anti-
gens, which may induce antibodies cross-reactive with natural
cytokines and thus inhibit the function of natural cytokines.
The cross-reactive antibodies are called endogenous anti-natu-
ral cytokine antibodies. Based on this, they developed a novel
approach to generate endogenous anti-TNF-a antibody.
Brieﬂy, mouse TNF-a was replaced in part by foreign Th epi-
tope sequences to construct TNF-amutantsmodiﬁed by Th epi-
topes. The mutants lost the activity of natural TNF-a, but were
immunogenic. Mice immunized with the mutants may produce
antibodies that can inhibit natural TNF-a both in vivo and
in vitro. In addition, the authors proved the safety and high per-
formance of this approach. Since BAFF and TNF-a are mem-
bers of the same family and structurally similar, the new strategy
of inhibiting TNF-a activity may also be applied to BAFF.
In this study, we generated several candidate immune inhibi-
tors of human BAFF by conjugating foreign immunodominant
Th epitope to the N- or C-terminus of diﬀerent BAFF mutants.
The recombined proteins were express in Escherichia coli
(E. coli) and puriﬁed by Ni-NTA chromatography. After
BALB/c and hu-SCID mice were immunized with the puriﬁed
proteins, the neutralizing antibodies against human sBAFFwere
detected in sera from themice. This studymayprovide a valuable
strategy for treating BAFF-associated autoimmune diseases.2. Materials and methods
2.1. Preparation of recombinant sBAFF mutant proteins modiﬁed by Th
epitopes
cDNA encoding human soluble BAFF (sBAFF) was obtained by re-
verse-transcription PCR with total RNA extracted from human tonsil
tissue and then cloned into pUC19 plasmid (named pUC19-sBAFF).
DNA sequences encoding diﬀerent sBAFF mutants (msBAFFs) wereblished by Elsevier B.V. All rights reserved.
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The mutants were named msBAFF1 (amino acids 134–271 of sBAFF),
msBAFF2 (amino acids 134–256 of sBAFF), msBAFF3 (amino acids
149–285 of sBAFF), msBAFF4 (amino acids 164–285 of sBAFF) and
msBAFF5 (amino acids 217–224 of sBAFF replaced by two glycines).
DNA sequences encoding Th epitope (SALLSSDITASVNCA) from
hen egg-white lysozyme (HEL) were obtained by oligonucleotide syn-
thesis and then ligated with diﬀerent cDNA mutants. After sequencing,
the recombinant plasmids were digested with BamHI and HindIII, and
the recombinant genes were recovered and cloned into pQE80L vector.
Following identiﬁcation by restriction enzyme digestion, the positive
recombinant expression plasmids were obtained, namely, pQE80L-
HELmsBAFF1, pQE80L-HELmsBAFF2, pQE80L-HELmsBAFF3,
pQE80L-HELmsBAFF4 and pQE80L-HELmsBAFF5.The recombi-
nant genes were transformed into E. coli DH5a and induced by IPTG
to express. The expressed proteins were puriﬁed according to the
instructions of the kits from Qiagen Co. Soluble HELmsBAFF5 pro-
tein was puriﬁed by Ni-NTA chromatography under natural (non-
denaturing) condition, whereas proteins expressed as inclusion body
(HELmsBAFF1, HELmsBAFF2, HELmsBAFF3 and HELmsBAFF4
proteins) were puriﬁed by Ni-NTA chromatography under denaturing
condition. Proteins puriﬁed under denaturing condition were dialyzed
to get renatured. The purity of recombinant proteins was determined
by SDS–PAGE.
2.2. Immunization of BALB/c mice
BALB/c mice, aged 5–6 weeks, were obtained from the Laboratory
Animal Center of The Third Military Medical University, which were
housed and manipulated according to the local conventions for the
care and use of laboratory animals (Chongqing). They were random-
ized to six groups, namely, the ﬁve test groups and the control group.
Mice of the test groups were primarily immunized by intraperitoneal
injection of 100 lg recombinant protein in phosphate-buﬀered saline
(PBS) emulsiﬁed 1:1 in complete Freund’s adjuvant (CFA), received
booster injections of incomplete Freund’s adjuvant (IFA) after two
weeks, and then were injected with only 100 lg recombinant protein
after an additional week. Control mice received PBS in CFA or
IFA. Blood samples were drawn via caudal vein and sera fractionated
3, 4, 6, 8, and 10 weeks after primary immunization.
2.3. Analysis of antibodies in sera from immunized BALB/c mice
The titre of anti-sBAFF antibody was measured by ELISA. 96-well
ELISA plates were coated overnight at 4 C with 10 lg/ml sBAFF. The
plates were washed with PBST buﬀer and blocked with blocking buﬀer
for 2 h at 37 C. After four washes, serially diluted mouse sera were
added into the wells (100 ll per well) and incubated for 2 h at 37 C.
After four washes, HRP-conjugated goat anti-mouse IgG diluted at
1:2000 was added (100 ll per well) and incubated for 1 h at 37 C.
The wells were washed four times and incubated with o-phenylenedi-
amine dihydrochloride (OPD) substrate for 15 min at 37 C. The reac-
tion was stopped with 2 N H2SO4 and the optical density at 492 nm
was measured with an ELISA plate reader.
2.4. In vitro neutralization assay of sera from immunized BALB/c mice
The neutralization assay was performed in 96-well ﬂat bottom
plates. Brieﬂy, diﬀerent volumes (10, 5, 2, 1, 0.5, 0.1 ll) of sera from
immunized BALA/c mice were mixed with 10 ll (2 lg) of recombinant
sBAFF or 5 ll of sera from rheumatoid arthritis (RA) patients; the
ﬁnal volume in each well was adjusted to 100 ll with RPMI-1640.
After incubation for 1 h at 37 C, 100 ll of 1 · 106/ ml human periph-
eral blood lymphocyte (hu-PBL) suspension was added and the plates
were incubated for 72 h at 37 C in air containing 5% CO2. Lympho-
cyte proliferation was subjected to the MTT assay.
2.5. Construction and immunization of hu-SCID chimeric mice
Four- to ﬁve-week-old pathogen-free female SCID mice were pur-
chased from Beijing Laboratory Animal Research Center and raised
with sterile feed and tap water in a sterile isolator. All procedures
involving animals were performed in accordance with the local conven-
tions for the care and use of laboratory animals (Chongqing). Human
lymphocyte concentration was adjusted to 8 · 107/ml with PBS. Each
SCID mouse was injected intraperitoneally with 0.5 ml of human lym-
phocytes (4 · 107). Next day the mice injected with human lympho-
cytes were divided into two test groups and one control group. Miceof the two test groups were immunized with 30 lg of HELmsBAFF3
or HELmsBAFF5 in PBS emulsiﬁed 1:1 in CFA, while mice of the
control group were immunized with PBS emulsiﬁed 1:1 in CFA. Three
subsequent booster injections were performed using IFA at 2-week
intervals. The mice of the two test groups were injected with 20 lg pro-
tein one week after the fourth immunization.
2.6. Assay of human IgG content and anti-sBAFF antibodies in sera from
hu-SCID mice
Sera were collected before and 4, 6, 8, and 10 weeks after trans-
plantation. Human IgG content of sera from hu-SCID mice was mea-
sured with a ‘‘sandwich’’ ELISA method; the titre of anti-human
sBAFF antibody was determined by ELISA.
2.7. In vitro neutralization assay of sera from hu-SCID mice
Diﬀerent volumes (20, 10, 5, 2, 1, 0.5 ll) of sera from immunized hu-
SCID mice were mixed with 10 ll (2 lg) of recombinant sBAFF. After
a while, the neutralization ability of sera from immunized hu-SCID
mice was subjected to lymphocyte proliferation assay.
2.8. Statistical analysis
Data are expressed as means ± S.E.M. Statistical analyses were per-
formed using the software SPSS 11.5. Two-way ANOVA and multiple
comparisons of mean values were conducted. A P value less than 0.05
was considered statistically signiﬁcant.3. Results
3.1. Preparation of recombinant proteins
The recombinant genes were successfully constructed and
cloned into the expression plasmid pQE80L. E. coli DH5a car-
rying the recombinant plasmids expressed the target proteins
under IPTG induction. The yield of recombinant proteins ac-
counted for 30–40% of total bacterial protein (Fig. 1A). The
molecular weight of the recombinant proteins ranged from
19 to 21 kDa. Following Ni-NTA chromatography, SDS–
PAGE of the target proteins revealed a single band
(Fig. 1B). The purity of recombinant proteins was more than
90% as determined by densitometric scanning.
3.2. Antibody titres in sera from immunized BALB/c mice
To assess the ability of the ﬁve recombinant proteins to elicit
antibodies that are cross-reactive with sBAFF, BALB/c mice
were immunized intraperitoneally on days 0, 14 and 21. Sera
were collected from all animals and were analyzed by ELISA
for the presence of speciﬁc anti-sBAFF antibodies. After a sec-
ond immunization, all mice immunized with recombinant pro-
teins produced human sBAFF-speciﬁc antibodies at high
levels. Antibody titer reached a peak in week 6 after all three
immunizations. The mean antibody titers were found to range
from 1:12800 to 1:25600 in the HELmsBAFF1, HELms-
BAFF2, and HELmsBAFF4 groups and be higher than
1:51200 in the HELmsBAFF3 and HELmsBAFF5 groups.
No antibody against BAFF was detected in control mice
‘‘immunized’’ with PBS and adjuvant. The results indicated
that recombinant sBAFF mutants modiﬁed with Th epitopes
induced polyclonal antibodies that are cross-reactive with
sBAFF in vivo.
3.3. Inhibition of human sBAFF by sera from immunized
BALB/c mice
In vitro neutralization assay was used to assess the ability of
sera from immunized BALB/c mice to inhibit sBAFF’s stimu-
lation of lymphocyte proliferation. The results indicated that
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Fig. 2. Inhibition of the proliferation-inducing activity of sBAFF by
the sera of immunized BALA/c mice. The diﬀerent volumes of sera
from immunized mice were mixed with 2 lg of recombinant sBAFF
(A) or 5 ll of rheumatoid arthritis patient serum (B) and incubated for
1 h at 37 C. Human peripheral lymphocytes were added and
incubated for 72 h at 37 C. Lymphocyte proliferation was measured
by the MTT method.
Mr(kDa) M 1 2 3 4 5 6 
A
Mr(kDa) M 1 2 3 4 5 
B
97.4
66.2
43.0
31.0
20.1
14.4
97.4
66.2
43.0
31.0
20.1
14.4
Fig. 1. Expression, puriﬁcation of the recombinant proteins. (A) M:
marker, lanes 1: induced DH5a/pQE80L, lanes 2: induced DH5a/
pQE80L-HELmsBAFF1, lanes 3: induced DH5a/pQE80L-HELms-
BAFF2, lanes 4: induced DH5a/pQE80L-HELmsBAFF3, lanes 5:
induced DH5a/pQE80L-HELmsBAFF4, lanes 6: induced DH5a/pQE-
80L-HELmsBAFF5. (B) M: marker, lanes 1: puriﬁed HELmsBAFF1,
lanes 2: puriﬁed HELmsBAFF2, lanes 3: puriﬁed HELmsBAFF3,
lanes 4: puriﬁed HELmsBAFF4, lanes 5: puriﬁed HELmsBAFF5.
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creased slightly with increasing volume of sera, while absor-
bance of wells added with sera from mice immunized with
recombinant proteins decreased with increasing volume of
sera, and the most signiﬁcant reduction in absorbance was
observed with sera from mice immunized with HELmsBAFF3
or HELmsBAFF5 (Fig. 2). There were signiﬁcant diﬀerences
between the experimental groups and the control group
(P < 0.01), demonstrating that the speciﬁc antibodies in mice
sera inhibited the lymphocyte proliferation-inducing activity
of sBAFF in a dose-dependent manner.
3.4. Content of human IgG and anti-sBAFF antibodies in sera
from hu-SCID chimeric mice
To determine whether the recombinant proteins could in-
duce human lymphocytes to produce antibodies that are
cross-reactive with sBAFF, SCID mice were injected intraper-
itoneally with human lymphocytes to reestablish the immunity,
and then they were immunized with HELmsBAFF3 or
HELmsBAFF5. Sera were collected before and 4, 6, 8, and
10 weeks after lymphocyte transplantation for the measure-
ment of human IgG content and anti-sBAFF antibodies. The
results indicated that human IgG was not detected in the
pre-transplantation sera, but in sera following lymphocyte
transplantation. The level of human IgG increased with time
and reached a peak in week 8 after lymphocyte transplantation
(Table 1). The levels of human IgG in sera of the experimental
groups were higher than those of the control group (P < 0.01).
After a third immunization, anti-sBAFF IgG was detected in
sera from the experimental groups. The titres of anti-sBAFF
antibodies increased after the last immunization. Nevertheless,no antibody against sBAFF was detected in sera from control
mice (Table 2). The results indicated that hu-SCID chimeric
mice were successfully constructed and the recombinant pro-
teins could induce human lymphocytes to produce polyclonal
antibodies that are cross-reactive with BAFF.
3.5. Inhibition of human sBFFF by sera from immunized hu-
SCID mice
Sera were collected after the last immunization and their
ability to inhibit the lymphocyte proliferation-inducing activity
of sBAFF was assessed. The results showed that absorbance of
wells added with sera from hu-SCID mice immunized with the
recombinant proteins decreased with increasing volume of
sera, while absorbance of wells added with sera from control
mice did not change signiﬁcantly (Fig. 3), demonstrating that
anti-sBAFF antibodies in mouse sera partially inhibited the
lymphocyte proliferation-inducing activity of sBAFF.4. Discussion
It has been demonstrated that overexpression of BAFF is
closely associated with the pathogenesis and progression of
Table 1
Human IgG levels in the sera of SCID engrafted with human lymphocytes
Number Weeks after engraftment Immunized group
PBS HELmsBAFF3 HELmsBAFF5
1 0 0 0 0
2 4 250.2 ± 43.1 423.5 ± 32.6 452.2 ± 54.4
3 6 365.4 ± 52.3 740.7 ± 88.6 795.4 ± 113.2
4 8 527.7 ± 77.5 953.5 ± 102.4 1043.8 ± 165.8
5 10 463.8 ± 36.8 825.3 ± 66.7 915.3 ± 87.6
Table 2
The geometric mean titres (GMTs) of anti-sBAFF antibodies in the sera of SCID engrafted with human lymphocytes
Number Weeks after engraftment Immunized group
PBS HELmsBAFF3 HELmsBAFF5
1 0 0 0 0
2 4 0 0 0
3 6 0 1:14 1:26
4 8 0 1:139 1:183
5 10 0 1:117 1:149
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Fig. 3. Inhibition of the proliferation-inducing activity of sBAFF by
the sera from immunized hu-SCID mice. Diﬀerent volumes of the sera
from immunized hu-SCID mice were mixed with 10 ll (2 lg) of
recombinant sBAFF and incubated for 1 h. Human peripheral
lymphocytes were added and lymphocyte proliferation was measured
by the MTT method.
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erythematosus (SLE), rheumatoid arthritis (RA) and Sjogren’s
syndrome (SS) and suppression of BAFF by anti-BAFF anti-
bodies or soluble BAFF receptors ameliorate the symptoms of
these conditions [14–16]. However, the therapy with antibody
or soluble receptor may bring some disadvantages, for exam-
ple, it is impractical and torturing in that repeated administra-
tion of exogenous protein therapeutics is required to inhibit
BAFF; moreover, anti-BAFF antibodies and soluble BAFF
receptors are potentially immunogenic compounds that may
elicit unwanted antibody responses, thus limiting the long-term
eﬃcacy of the therapy.
It has recently demonstrated that truncated self proteins can
provoke immune response to natural proteins through cross-
recognition, and that such immunity is further enhanced by
speciﬁc amino acid substitution that promotes T helper cell re-
sponses [22]. Mice immunized with foreign Th epitope-modi-
ﬁed recombinant cytokines have been shown to generatelong-term antibody responses against natural cytokines; more-
over, the pathological symptoms associated with these cyto-
kines were ameliorated in the immunized mice [21].
Accordingly, we ﬁrst constructed sBAFF mutants and modi-
ﬁed them with foreign Th epitopes. Since the mutation sites
may inﬂuence the ability of recombinant mutants to elicit
anti-sBAFF antibodies, ﬁve diﬀerent sBAFF mutants modiﬁed
with foreign Th epitopes were constructed in the study. To fur-
ther assess the ability of recombinant proteins to induce anti-
human BAFF antibodies and screen the most potent BAFF
inhibitors, we carried out animal experiments.
In the present study, we ﬁrst immunized immunocompetent
BALB/c with recombinant proteins. In immunocompetent
mice, recombinant human sBAFF and HEL Th-epitope mod-
iﬁed msBAFF are foreign proteins and may induce corre-
sponding antibodies. Nevertheless, it is not clear whether the
resulting antibodies are speciﬁc to natural human sBAFF,
and the type and titre of antibodies cannot be determined.
Hence, the purpose of experiments with immunocompetent
mice was to determine whether recombinant proteins may in-
duce anti-human sBAFF antibodies and the titre of them
and thus to screen recombinant proteins that may induce high
tetres of anti-human sBAFF antibodies, so as to provide a ba-
sis for selecting appropriate antigens. The results demonstrated
that relatively high titres of anti-human BAFF antibodies were
produced in sera of mice immunized with either of these re-
combinant proteins, and that sera from the immunized mice
signiﬁcantly inhibited the ability of recombinant sBAFF and
natural sBAFF to stimulate lymphocyte proliferation. There-
fore, as novel proteins, the recombinant mutant proteins are
structurally distinct from wild-type sBAFF, but they can also
induce mice to produce antibodies that are cross-reactive with
wild-type sBAFF.
To determine whether the recombinant proteins induce hu-
man lymphocytes to produce anti-human sBAFF antibodies,
the human-SCID chimeric model was established and then
immunized with the recombinant proteins. SCID (severe com-
bined immunodeﬁciency mice) mice were ﬁrst bred by Bosma
et al. [23] in 1983. A prominent characteristic of SCID mice
H. Gao et al. / FEBS Letters 581 (2007) 581–586 585is lack of functional T and B cells, which makes them a favor-
able living host system for xenotransplantation [24]. SCID
mice can host human lymphocytes and thus become hu-SCID
mice, which is an ideal model for study human immunologic
mechanisms [25,26]. At present, it is impossible to perform hu-
man experiments with the recombinant proteins. In this case,
experiments with hu-SCID mice may shed light on the induc-
tion of endogenous anti-human sBAFF antibodies by Th-epi-
tope modiﬁed msBAFF in human body.
High titre of human IgG was produced in SCID mice 4
weeks after lymphocyte transplantation, which increased with
time and reached a peak in week 8. The ﬁnding demonstrated
that human lymphocytes survived in SCID mice and the
immunity of SCID mice was reestablished. To evaluate the
immunogenicity of the recombinant proteins, we immunized
mice with them. After a third immunization, anti-sBAFF
IgG was detected in sera from some mice of the test groups.
The titres of anti-sBAFF antibodies reached a peak after the
last immunization, and there were signiﬁcant diﬀerences in
the titre between the test groups and the control group. In
addition, the IgG levels of the test groups were higher than
that of the control group, which suggested that the recombi-
nant proteins could break down the tolerance and further stim-
ulate the human lymphocytes proliferation, diﬀerentiation and
secretion of IgG. The results indicated that the recombinant
proteins could induce human lymphocytes to produce anti-
sBAFF antibodies. Nevertheless, the titre was relatively low
in sera of SCID mice and further experiments with more eﬀec-
tive animal models are required.
Taken together, human sBAFF mutants modiﬁed with for-
eign Th epitopes have been successfully prepared, which can
induce antibodies that are cross-reactive with human sBAFF.
This study provides a new strategy for the treatment of
BAFF-related autoimmune diseases.
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